Melanotan I
Lyophilized research reference material. Released with a per-lot Certificate of Analysis. For laboratory research use only.
- All products currently listed on this site are for research purposes ONLY.
- All products sold on this website are intended for research and identification purposes only.
- These products are not intended for human dosing, injections, or ingestion.
- Peptides are strictly for laboratory, academic, or institutional research and not for human or animal consumption.
Research background
Melanotan I (afamelanotide) is a synthetic linear tridecapeptide analog of alpha-melanocyte-stimulating hormone with selective potency at the MC1 receptor, the principal regulator of eumelanin synthesis. Research describes MC1R-mediated melanogenesis and photoprotection.
Afamelanotide has completed clinical development for the rare photodermatosis erythropoietic protoporphyria.
Summary of published scientific literature provided for laboratory research reference only. It is not a claim of safety, efficacy, or suitability for any use, and does not describe or recommend any human or veterinary use.
Selected references
- Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine. 2015;373(1):48-59.
- Fabrikant J, et al. A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of Drugs in Dermatology. 2013;12(7):775-779.
- Dorr RT, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin. Photochemistry and Photobiology. 2004;80:551-557.
Trademarks & attribution
Afamelanotide is marketed as Scenesse(R) by Clinuvel Pharmaceuticals. That trademark is the property of its owner. Catalyst Research Labs is not affiliated with Clinuvel. Supplied as reference material only.
